KPVCalm inflammation where it starts — gut, skin, and wounds.
A three-amino-acid fragment of alpha-MSH studied for gut inflammation, wound healing, and inflammatory skin conditions.
KPV is the short peptide people want when inflammation will not settle — stubborn gut flare, slow wound closure, irritated skin. An FDA advisory committee recommended it for compounding in July 2026. Join the waitlist for first access when pharmacy-sourced KPV can be evaluated through AlphaMD.
By joining, you opt in to launch and marketing email about KPV from AlphaMD. You can unsubscribe at any time.
- U.S. compounding pharmacies only
- Discreet shipping
- 100% confidential
Why KPV Gets Attention
Three amino acids built to quiet inflammatory signaling.
KPV is three amino acids long — lysine, proline, valine — the tail end of alpha-melanocyte-stimulating hormone, a hormone your body already makes with well-documented anti-inflammatory properties. Researchers trimmed it to these three residues to keep the calming effect while leaving pigmentation and appetite effects of the full hormone behind.
The mechanism is a big part of the appeal. Instead of docking on a surface receptor, KPV appears to enter cells via PepT1 — a transporter more abundant in inflamed intestinal tissue. Inside, it blocks IκB kinase and keeps NF-κB, the master switch for inflammatory gene expression, from reaching the nucleus. Less NF-κB traffic means less TNF-α, IL-1β, and IL-6.
That story is built from cell cultures and mice — elegant, mechanism-backed, and still without published human trials administering KPV. In July 2026 an FDA advisory committee recommended adding it to the compounding list anyway, 8 to 6 with one abstention, over staff advice against. The waitlist is how you get first access when pharmacy compounding is lawful.
Where KPV Stands Today
- Recommended for compoundingAdvisory vote 8–6 (1 abstention), July 23, 2026
- FDA scientists advised against itAgency staff recommended no; the advisory committee voted yes 8–6
- No human studies yetFDA found zero clinical trials administering KPV to people
- Not an FDA-approved drugNo approved indication, no approved dosing label
- Unsettled in tested sportNot named by WADA, but the S0 catch-all can still reach it
- Prescription-only at launchProvider evaluation and intake required — no direct purchase
Final compounding authorization still needs FDA rulemaking. Join the waitlist for first access when a trusted pharmacy can lawfully produce and test KPV.
What You May Get From KPV
The inflammation and repair upsides people want — with a clear read on the research behind each one.
Calming gut inflammation
The deepest research line. Oral KPV reduced disease activity, weight loss, and colonic inflammatory cytokines across two mouse models of colitis — the gut-calm story members ask about.
Animal dataShutting down NF-κB signaling
In human intestinal and immune cell lines, KPV prevented IκB-α degradation and cut IL-8 output — one of the clearest peptide mechanisms in this category.
Lab dataWound closure and skin repair
Accelerated healing in a corneal epithelial wound model and improved re-epithelialization in rodent skin. FDA nominations focused on topical preparations.
Animal dataIt survives being swallowed
Rare for a peptide. KPV stayed active when given by mouth in animal colitis work — though several studies used engineered delivery particles, not ordinary capsules.
Animal dataInflammatory skin conditions
Eczema, psoriasis, and rosacea are common reasons people ask about topical KPV. The mechanism supports the interest; formal human trials have not been published yet.
Theory onlyWho KPV May Be A Fit For
A provider makes this call with you after reviewing your history and labs.
- Living with an inflammatory gut condition — ulcerative colitis or Crohn's, managed alongside your gastroenterologist.
- Fighting a stubborn inflammatory skin condition that standard dermatologic care has not settled down.
- Healing a wound that is taking too long — once it has been examined in person and infection has been ruled out.
- Wanting a mechanism-backed option with research still largely preclinical — and a provider watching the plan.
- Already an AlphaMD member who wants anything new folded into a plan someone is actually watching.
Who Should Skip It
Practical fit filters — a provider will decline when these apply.
- You need a diagnosis first. Persistent gut or skin symptoms need a workup — IBD, celiac disease, and infection can all look like "inflammation" from the outside.
- You plan to inject it. The nominations the FDA reviewed were topical. Injection is a different exposure with little behind it.
- You're pregnant, nursing, or trying to conceive. No safety data exists in these groups.
- You compete in a tested sport and cannot afford ambiguity — KPV is unnamed by WADA, which is not the same as cleared.
- You're under 18, or you are unwilling to complete intake and follow-up.
What To Know About Risks
Published human side-effect lists for KPV do not exist yet. Here is what is known from the research and manufacturing picture.
No published human side-effect profile
FDA found no clinical safety studies. That means dosing and monitoring belong with a provider when this launches — not with a forum protocol.
Topical irritation
Redness, itching, burning, or contact sensitivity are plausible with any topical peptide preparation — from the peptide, the vehicle, or both.
Immune reactions to the peptide or its impurities
FDA flagged aggregation and immunogenicity as unresolved. Peptides can clump during manufacturing and storage, and aggregates are more likely to provoke an immune response.
Route still matters
Animal results came from oral dosing and from engineered nanoparticles that carried KPV to inflamed colon. Ordinary capsules, creams, and injections are not those delivery systems.
Suppressing inflammation you need
Inflammation clears debris and fights infection. Long-term dampening of that signal in humans has not been studied either way.
Gray-market product quality
Most peptide harm traces to what was actually in the container. Pharmacy-tested product is the reason to wait for a legitimate launch.
Pharmacy-Sourced Beats Gray-Market Guesswork
KPV is short and cheap to synthesize, which is why so much of it is sold online as a "research chemical." Independent testing of gray-market peptide vials keeps turning up the same problems.
Gray-market vials
- Peptide content well under — or over — what the label claims
- Bacterial endotoxin from non-sterile production — a fever and sepsis risk you inject directly
- Residual synthesis solvents, heavy metals, and truncated peptide fragments
- Certificates of analysis that are copied, expired, or for an entirely different lot
- No prescriber, no recall path, and no one accountable if you're harmed
A U.S. compounding pharmacy
- State-licensed, FDA-inspected facility working from a real prescription
- Sterile compounding standards for anything injected, with documented process controls
- Third-party potency, sterility, and endotoxin testing tied to your specific lot
- A provider who sets your dose, reviews your labs, and owns follow-up
- Traceability — if a lot is bad, it can be found, pulled, and reported
When KPV launches with AlphaMD, members get pharmacy-sourced product after a provider evaluation — not a cream or vial from an unverified seller.
Educational Resources
Deeper reading on what KPV is, what the research shows, and why sourcing decides most of the risk.
KPV benefits, risks, and side effects: what you need to know
The long-form deep dive: the alpha-MSH relationship, colitis research, topical vs injectable questions, and what the FDA said.
The FDA compounding votes on BPC-157, TB-500, KPV and MOTs-c
What the July 2026 advisory committee decided, why the votes were close, and what still has to happen before compounding opens.
Are your peptides even real? Why 1 in 5 tested vials came back mislabeled
What third-party assays keep finding inside gray-market vials — wrong potency, wrong sequence, and mismatched certificates.
Frequently Asked Questions
Still deciding? Message the team — you don't need to be a member to ask.
Ask a QuestionFirst access when pharmacy-compounded KPV can be offered through AlphaMD — provider evaluation, intake, and product from a U.S. compounding pharmacy with lot-level testing. You hear as soon as launch is real.
In July 2026 an FDA advisory committee recommended KPV for the 503A bulk-substances list. Final rulemaking still has to finish, which could run into 2027 or beyond. Once a pharmacy AlphaMD trusts can lawfully produce and test it, the waitlist gets the email that week.
Not yet. Nothing on this page is for sale. If a clinic is offering KPV today, ask which licensed U.S. pharmacy compounded it and for lot-specific testing. Most cannot show either.
Not for KPV administered to people. FDA reviewers found no clinical study giving KPV to human participants. There is strong mechanism work and animal data — enough interest to queue it for compounding, not enough to invent clinical certainty.
Research has mostly been oral or topical, and FDA nominations focused on topical preparations. Route and dose belong in a provider consult — there is no approved label to copy.
Different molecules with overlapping reputations. KPV damps inflammatory signaling; BPC-157 is studied more for tissue repair and new blood-vessel growth. BPC-157 has some human ulcerative colitis data; KPV does not yet. Stacking them has not been adequately trialled.
No interaction is known. Raising it at your next visit keeps testosterone, labs, and anything new in the same chart.
Possession is not a criminal matter for individuals, but KPV is not an approved drug and selling it for human use is not lawful. The legitimate route is a prescription after provider evaluation, filled by a licensed compounding pharmacy.
Pricing is not set until a supplier is locked. When it is, it will be published the same way TRT pricing is: one clear number, per month.
Explore Other Peptides
Five more on the same July 2026 compounding slate — join each waitlist for first access when they launch.
Get First Access to KPV
Join the waitlist for pharmacy-sourced KPV through AlphaMD — provider evaluation, tested product, discreet shipping. Already a member? Bring peptides up at your next visit or book a consult to get intake done early.
By joining, you opt in to launch and marketing email about KPV from AlphaMD. You can unsubscribe at any time.
No insurance needed · Cancel anytime · 100% confidential
Legal Disclaimer
KPV is not an FDA-approved drug and is not currently available for sale or prescription through AlphaMD. Nothing on this page is an offer to sell, and nothing here is medical advice. Statements about potential benefits describe published preclinical laboratory and animal research and are not claims about outcomes for any individual. Peptide therapy, if and when offered, will require a consultation with a licensed medical professional, a completed medical intake, and appropriate laboratory testing; it is not appropriate for everyone. KPV is not named on the World Anti-Doping Agency Prohibited List, but the List's non-approved substances class is a catch-all that can still reach substances lacking regulatory approval; athletes subject to testing should confirm status with their anti-doping organization before use.
Medical services are provided by independent, licensed providers through AlphaMD's affiliated professional practices. AlphaMD provides administrative and technology services and does not practice medicine.